Management of Chronic Kidney Disease Stages 1–3
Clinical Bottom Line: Screening and Monitoring in Subpopulations
Indirect evidence from the comparative effectiveness review suggests that screening populations at high risk for developing chronic kidney disease (patients with diabetes, hypertension, or cardiovascular disease) and monitoring patients who already have early signs of kidney disease for albuminuria and the estimated glomerular filtration rate may help identify those patients with chronic kidney disease stages 1–3 who might benefit from early initiation of treatment with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and/or statins.
- Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment. Comparative Effectiveness Review No. 37 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I). Rockville, MD: Agency for Healthcare Research and Quality; January 2012. AHRQ Publication No. 11(12)-EHC075-EF. Available at www.effectivehealthcare.ahrq.gov/ckd.cfm.
Your slide tray is being processed.